The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

Cancer Immunology, Immunotherapy

Volumn 58, Issue 7, 2009, Pages 1033-1045

  Galustian, Christine ^a   Meyer, Brendan ^a   Labarthe, Marie Christine ^a   Dredge, Keith ^a,d   Klaschka, Deborah ^a   Henry, Jake ^a   Todryk, Stephen ^b   Chen, Roger ^c   Muller, George ^c   Stirling, David ^c   Schafer, Peter ^c   Bartlett, J Blake ^c   Dalgleish, Angus G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CELGENE CORPORATION   (United States)

^d Progen Pharmaceuticals Limited   (Australia)

Author keywords

IMiDs ; Immunomodulatory drugs; Lenalidomide; Pomalidomide; T regulatory cells

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMIDS; INTERLEUKIN 10; INTERLEUKIN 2; LENALIDOMIDE; POMALIDOMIDE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVITY; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG ACTIVITY; LYMPH NODE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MONOCYTE; MOUSE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; MICE; MICE, INBRED BALB C; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, OX40; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES, REGULATORY; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA;

EID: 67349107194     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0620-4     Document Type: Article

References (67)

1. PA Antony CM Paulos M Ahmadzadeh A Akpinarli DC Palmer N Sato A Kaiser CS Hinrichs CA Klebanoff Y Tagaya NP Restifo 2006 Interleukin-2-dependent mechanisms of tolerance and immunity in vivo J Immunol 176 5255 5266
2. PA Antony NP Restifo 2002 Do CD4+CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother 25 202 206
3. C Baecher-Allan DE Anderson 2006 Immune regulation in tumor-bearing hosts Curr Opin Immunol 18 214 219 (Pubitemid 43327305)
4. JB Bartlett K Dredge AG Dalgleish 2004 The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 314 322 (Pubitemid 38525287)
5. JB Bartlett A Michael IA Clarke K Dredge S Nicholson H Kristeleit A Polychronis H Pandha GW Muller DI Stirling J Zeldis AG Dalgleish 2004 Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers Br J Cancer 90 955 961 (Pubitemid 38495811)
6. E Bettelli M Dastrange M Oukka 2005 Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells Proc Natl Acad Sci USA 102 5138 5143 (Pubitemid 40503752)
7. high FOXP3+ regulatory T cells in patients with multiple myeloma Blood 107 3940 3949 (Pubitemid 43726800)
8. M Beyer JL Schultze 2006 Regulatory T cells in cancer Blood 108 804 811 (Pubitemid 44154611)
9. B Calmels S Paul N Futin C Ledoux F Stoeckel B Acres 2005 Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L Cancer Gene Ther 12 198 205 (Pubitemid 40205100)
10. A Chanan-Khan KC Miller K Takeshita A Koryzna K Donohue ZP Bernstein A Mohr D Klippenstein P Wallace JB Zeldis C Berger MS Czuczman 2005 Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL) Blood 106 3348 3352 (Pubitemid 41609163)
11. DH Chang N Liu V Klimek H Hassoun A Mazumder SD Nimer S Jagannath MV Dhodapkar 2006 Enhancement of ligand dependent activation of human natural killer T cells by Lenalidomide: therapeutic implications Blood 108 618 621 (Pubitemid 44061362)
12. TJ Curiel G Coukos L Zou X Alvarez P Cheng P Mottram M Evdemon-Hogan JR Conejo-Garcia L Zhang M Burow Y Zhu S Wei I Kryczek B Daniel A Gordon L Myers A Lackner ML Disis KL Knutson L Chen W Zou 2004 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 942 949 (Pubitemid 39273735)
13. J Dannull Z Su D Rizzieri BK Yang D Coleman D Yancey A Zhang P Dahm N Chao E Gilboa J Vieweg 2005 Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells J Clin Invest 115 3623 3633 (Pubitemid 43121851)
14. FE Davies N Raje T Hideshima S Lentzsch G Young YT Tai B Lin K Podar D Gupta D Chauhan SP Treon PG Richardson RL Schlossman GJ Morgan GW Muller DI Stirling KC Anderson 2001 Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood 98 210 216
15. LM de Parseval H Brady E Glezer N Richard G Muller CL Morris D Stirling K Chan 2004 Novel immunomodulatory drugs (IMiDs(R)): a potential, new therapy for {beta}-hemoglobinopathies ASH Annu Meet Abstr 104 3740
16. ACP Diederichsen J Zeuthen PB Christensen T Kristensen 1999 Characterisation of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer Eur J Cancer 35 721 726 (Pubitemid 29258140)
17. MA Dimopoulos A Spencer M Attal M Prince JL Harousseau A Dmoszynska Z Yu M Olesnyckyj J Zeldis R Knight 2005 Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) ASH Annu Meet Abstr 106 6
18. K Dredge JB Marriott SM Todryk GW Muller R Chen DI Stirling AG Dalgleish 2002 Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity J Immunol 168 4914 4919 (Pubitemid 34495953)
19. JG Egen MS Kuhns JP Allison 2002 CTLA-4: new insights into its biological function and use in tumor immunotherapy Nat Immunol 3 611 618 (Pubitemid 34752469)
20. HA Fine L Kim PS Albert JP Duic H Ma W Zhang T Tohnya WD Figg C Royce 2007 A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors Clin Cancer Res 13 7101 7106 (Pubitemid 350276894)
21. F Foss 2006 Clinical experience with denileukin diftitox (ONTAK) Semin Oncol 33 S11 S16 (Pubitemid 43306775)
22. FM Foss 2000 DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology Clin Lymphoma 1 Suppl 1 S27 S31
23. C Galustian D Klaschka MC Labarthe JB Bartlett AG Dalgleish 2004 The immunomodulatory drug (IMID (R)) CC-4047 enhances the proliferation and anti-tumor function of gamma delta T cells J Immunother 27 S50
24. C Galustian MC Labarthe JB Bartlett AG Dalgleish 2004 Thalidomide-derived immunomodulatory drugs as therapeutic agents Expert Opin Biol Ther 4 1963 1970 (Pubitemid 39627147)
25. F Ghiringhelli N Larmonier E Schmitt A Parcellier D Cathelin C Garrido B Chauffert E Solary B Bonnotte F Martin 2004 CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative Eur J Immunol 34 336 344 (Pubitemid 39255944)
26. D Golgher E Jones F Powrie T Elliott A Gallimore 2002 Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens Eur J Immunol 32 3267 3275 (Pubitemid 35414884)
27. WA Hanekom J Hughes PA Haslett P Apolles V Ganiso R Allin E Goddard GD Hussey G Kaplan 2001 The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children J Infect Dis 184 1192 1196 (Pubitemid 33010474)
28. PA Haslett LG Corral M Albert G Kaplan 1998 Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset J Exp Med 187 1885 1892 (Pubitemid 28262451)
29. PA Haslett WA Hanekom G Muller G Kaplan 2003 Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro J Infect Dis 187 946 955 (Pubitemid 36337907)
30. T Hayashi T Hideshima M Akiyama K Podar H Yasui N Raje S Kumar D Chauhan SP Treon P Richardson KC Anderson 2005 Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application Br J Haematol 128 192 203
31. highFoxp3+ regulatory T cells bear functional skin-homing receptors J Immunol 177 4488 4494 (Pubitemid 44469779)
32. high regulatory T cells Blood 104 895 903 (Pubitemid 38970590)
33. S Hori S Sakaguchi 2004 Foxp3: a critical regulator of the development and function of regulatory T cells Microbes Infect 6 745 751 (Pubitemid 38781186)
34. F Ichihara K Kono A Takahashi H Kawaida H Sugai H Fujii 2003 Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers Clin Cancer Res 9 4404 4408 (Pubitemid 37248397)
35. E Jones M hm-Vicker AK Simon A Green F Powrie V Cerundolo A Gallimore 2002 Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice Cancer Immun 2 1 (Pubitemid 38957287)
36. H Jonuleit E Schmitt M Stassen A Tuettenberg J Knop AH Enk 2001 Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood J Exp Med 193 1285 1294 (Pubitemid 32524778)
37. KR Koh M Janz MY Mapara B Lemke D Stirling B Dorken M Zenke S Lentzsch 2005 Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis Blood 105 3833 3840 (Pubitemid 40656125)
38. RY Lan AA Ansari ZX Lian ME Gershwin 2005 Regulatory T cells: development, function and role in autoimmunity Autoimmun Rev 4 351 363 (Pubitemid 41080072)
39. S Lentzsch R LeBlanc K Podar F Davies B Lin T Hideshima L Catley DI Stirling KC Anderson 2003 Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo Leukemia 17 41 44 (Pubitemid 36175886)
40. A List S Kurtin DJ Roe A Buresh D Mahadevan D Fuchs L Rimsza R Heaton R Knight JB Zeldis 2005 Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 549 557 (Pubitemid 40204668)
41. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761 (Baltimore, Md: 1950)
42. P Loke JP Allison 2004 Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells Arthritis Res Ther 6 208 214 (Pubitemid 40124371)
43. JB Marriott IA Clarke K Dredge G Muller D Stirling AG Dalgleish 2002 Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells Clin Exp Immunol 130 75 84
44. N Mitsiades CS Mitsiades V Poulaki D Chauhan PG Richardson T Hideshima NC Munshi SP Treon KC Anderson 2002 Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood 99 4525 4530 (Pubitemid 34627223)
45. M Motta L Rassenti BJ Shelvin S Lerner TJ Kipps MJ Keating WG Wierda 2005 Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia Leukemia 19 1788 1793 (Pubitemid 41486157)
46. G Nocentini C Riccardi 2005 GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily Eur J Immunol 35 1016 1022 (Pubitemid 40542207)
47. EN Nolte-'t Hoen JP Wagenaar-Hilbers EP Boot CH Lin GJ Arkesteijn EW van LS Taams MH Wauben 2004 Identification of a CD4+CD25+ T cell subset committed in vivo to suppress antigen-specific T cell responses without additional stimulation Eur J Immunol 34 3016 3027 (Pubitemid 39549381)
48. E Olsen M Duvic A Frankel Y Kim A Martin E Vonderheid B Jegasothy G Wood M Gordon P Heald A Oseroff L Pinter-Brown G Bowen T Kuzel D Fivenson F Foss M Glode A Molina E Knobler S Stewart K Cooper S Stevens F Craig J Reuben P Bacha J Nichols 2001 Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma J Clin Oncol 19 376 388 (Pubitemid 32112849)
49. C Querfeld TM Kuzel J Guitart ST Rosen 2005 Preliminary results of a phase II study of CC-5013 (lenalidomide, revlimid (R)) in patients with cutaneous T-cell lymphoma Blood 106 936A 937A
50. E Sato SH Olson J Ahn B Bundy H Nishikawa F Qian AA Jungbluth D Frosina S Gnjatic C Ambrosone J Kepner T Odunsi G Ritter S Lele YT Chen H Ohtani LJ Old K Odunsi 2005 Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer PNAS 102 18538 18543 (Pubitemid 43011261)
51. SA Schey P Fields JB Bartlett IA Clarke G Ashan RD Knight M Streetly AG Dalgleish 2004 Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma J Clin Oncol 22 3269 3276 (Pubitemid 41103682)
52. LA Schubert E Jeffery Y Zhang F Ramsdell SF Ziegler 2001 Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation J Biol Chem 276 37672 37679 (Pubitemid 37384195)
53. EM Shevach 2002 CD4+CD25+ suppressor T cells: more questions than answers Nat Rev Immunol 2 389 400
54. MJ Streetly K Gyertson Y Daniel JB Zeldis M Kazmi SA Schey 2008 Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation Br J Haematol 141 41 51
55. RP Sutmuller LM van Duivenvoorde EA van TN Schumacher ME Wildenberg JP Allison RE Toes R Offringa CJ Melief 2001 Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses J Exp Med 194 823 832 (Pubitemid 32983017)
56. T Takahashi Y Kuniyasu M Toda N Sakaguchi M Itoh M Iwata J Shimizu S Sakaguchi 1998 Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state Int Immunol 10 1969 1980 (Pubitemid 28566059)
57. I Takeda S Ine N Killeen LC Ndhlovu K Murata S Satomi K Sugamura N Ishii 2004 Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells J Immunol 172 3580 3589 (Pubitemid 38337939)
58. SK Teo WA Colburn WG Tracewell KA Kook DI Stirling MS Jaworsky MA Scheffler SD Thomas OL Laskin 2004 Clinical pharmacokinetics of thalidomide Clin Pharmacokinet 43 311 327 (Pubitemid 38534754)
59. P Trzonkowski E Szmit J Mysliwska A Dobyszuk A Mysliwski 2004 CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction Clin Immunol 112 258 267
60. B Valzasina C Guiducci H Dislich N Killeen AD Weinberg MP Colombo 2005 Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR Blood 105 2845 2851 (Pubitemid 40446278)
61. B Valzasina S Piconese C Guiducci MP Colombo 2006 Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent Cancer Res 66 4488 4495
62. PT Walsh BM Benoit M Wysocka NM Dalton LA Turka AH Rook 2006 A role for regulatory T cells in cutaneous T-cell lymphoma; induction of a CD4+CD25+Foxp3+ T-cell phenotype associated with HTLV-1 infection J Invest Dermatol 126 690 692 (Pubitemid 43255661)
63. WZ Wei GP Morris YC Kong 2004 Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells Cancer Immunol Immunother 53 73 78 (Pubitemid 38161212)
64. AM Wolf D Wolf M Steurer G Gastl E Gunsilius B Grubeck-Loebenstein 2003 Increase of regulatory T cells in the peripheral blood of cancer patients Clin Cancer Res 9 606 612 (Pubitemid 36182591)
65. ZZ Yang AJ Novak MJ Stenson TE Witzig SM Ansell 2006 Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma Blood 107 3639 3646
66. E Zorn EA Nelson M Mohseni F Porcheray H Kim D Litsa R Bellucci E Raderschall C Canning RJ Soiffer DA Frank J Ritz 2006 IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo Blood 108 1571 1579 (Pubitemid 44316124)
67. W Zou 2006 Regulatory T cells, tumour immunity and immunotherapy Nat Rev Immunol 6 295 307